Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics presented additional data from its ongoing Phase 2 trials of Elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis. The data showed durable transfusion independence and improvements in patient-reported fatigue measures for lower-risk myelodysplastic syndromes. In myelofibrosis, Elritercept demonstrated benefits in hematopoiesis, cytopenias, spleen volume reduction, and symptom scores.
June 17, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Keros Therapeutics presented positive data from its Phase 2 trials of Elritercept (KER-050), showing durable transfusion independence in myelodysplastic syndromes and broader clinical benefits in myelofibrosis.
The positive data from the Phase 2 trials of Elritercept (KER-050) indicate potential efficacy in treating myelodysplastic syndromes and myelofibrosis. This could lead to increased investor confidence and a positive short-term impact on Keros Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100